Patents by Inventor Brigitte Gicquel

Brigitte Gicquel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8642011
    Abstract: The present invention relates to an isolated microorganism belonging to the genus Mycobacterium, characterized in that it comprises inactivating the gene Rv0757 that confers a PhoP? phenotype and inactivating a second gene that prevents the production of DIM (DIM-phenotype). Additionally, the present invention comprises the use of said microorganism for producing a vaccine for immunizing against or preventing tuberculosis.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: February 4, 2014
    Assignee: Universidad de Zaragoza
    Inventors: Carlos Martin Montanes, Brigitte Gicquel, Esther Perez Herran, Jesus Gonzalo Asensio, Ainhoa Arbues Arribas
  • Publication number: 20130022638
    Abstract: The present invention relates to an isolated microorganism belonging to the genus Mycobacterium, characterized in that it comprises inactivating the gene Rv0757 that confers a PhoP? phenotype and inactivating a second gene that prevents the production of DIM (DIM-phenotype). Additionally, the present invention comprises the use of said microorganism for producing a vaccine for immunizing against or preventing tuberculosis.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 24, 2013
    Applicant: Universidad de Zaragoza
    Inventors: Carlos Martin Montanes, Brigitte Gicquel, Esther Perez Herran, Jesus Gonzalo Asensio, Ainhoa Arbues Arribas
  • Patent number: 8287886
    Abstract: An isolated microorganism belonging to the genus Mycobacterium, having one or both of an inactivated gene Rv0757 that confers a PhoP? phenotype and an inactivated second gene which prevents the production of DIM (DIM? phenotype). Methods of making the microorganism, related pharmaceutical formulations and vaccines are also provided, as are related methods of treatment and vaccination. The pharmaceutical formulation may also serve as a vector or adjuvant.
    Type: Grant
    Filed: March 14, 2007
    Date of Patent: October 16, 2012
    Assignee: Universidad de Zaragoza
    Inventors: Carlos Martin Montanes, Brigitte Gicquel, Esther Perez Herran, Jesus Gonzalo Asensio, Ainhoa Arbues Arribas
  • Publication number: 20100129407
    Abstract: The present invention relates to an isolated microorganism belonging to the genus Mycobacterium, characterized in that it comprises inactivating the gene Rv0757 that confers a PhoP? phenotype and inactivating a second gene that prevents the production of DIM (DIM? phenotype). Additionally, the present invention comprises the use of said microorganism for producing a vaccine for immunizing against or preventing tuberculosis.
    Type: Application
    Filed: March 14, 2007
    Publication date: May 27, 2010
    Applicant: UNIVERSIDAD DE ZARAGOZA
    Inventors: Carlos Martin Montanes, Brigitte Gicquel, Esther Perez Herran, Jesus Gonzalo Asensio, Ainhoa Arbues Arribas
  • Publication number: 20100093007
    Abstract: The present invention relates to a method and kit of diagnosis of Immune Restoration Syndrome associated with tuberculosis (TB-IRS) in patients infected with tuberculosis (TB) as well as in HIV co-infected patients comprising detecting an acute increase in Th1 response following exposure to mycobacterial extract, referred as tuberculin or PPD (Purified Protein Derivative) as well as to the 16 kDa protein, but not to ESAT-6 or CFP-10, two antigens from mycobacterium tuberculosis.
    Type: Application
    Filed: September 7, 2006
    Publication date: April 15, 2010
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Brigitte Autran, Anne Bourgarit, Guislaine Carcelain, Valérie Martinez, Brigitte Gicquel, Daniel Sereni
  • Patent number: 7601350
    Abstract: Purified antibodies that bind to M. tuberculosis ERP protein are disclosed. In one embodiment, a purified antibody, which binds specifically with a polypeptide comprising SEQ ID NO: 39 or SEQ ID NO: 41 is provided. In some embodiments the polypeptide has a theoretical molecular weight of about 28 kDa. In other embodiments the polypeptide has an observed molecular weight of about 36 kDa, as determined by denaturing polyacrylamide gel electrophoresis (SDS-PAGE). The purified antibody may be a monoclonal or a polyclonal antibody. Further embodiments provide antibodies that does not bind specifically with M. leprae P28 protein. The antibodies of the invention have many uses including the identification of M. tuberculosis.
    Type: Grant
    Filed: January 15, 2003
    Date of Patent: October 13, 2009
    Assignee: Institut Pasteur
    Inventors: Brigitte Gicquel, Eng Mong Lim, Denis Portnoi, Francois-Xavier Berthet, Juliano Timm
  • Patent number: 7597896
    Abstract: The invention concerns Mycobacterium strains whereof the erp gene is modified and a vaccine composition containing same. The modification of the erp gene decreases the virulence and the persistence of the Mycobacterium strains.
    Type: Grant
    Filed: January 26, 2006
    Date of Patent: October 6, 2009
    Assignee: Institut Pasteur
    Inventors: Brigitte Gicquel, François-Xavier Berthet
  • Patent number: 7527788
    Abstract: Antibodies that bind to the M. tuberculosis Des protein are provided.
    Type: Grant
    Filed: February 21, 2006
    Date of Patent: May 5, 2009
    Assignee: Institut Pasteur
    Inventors: Mary Jackson, Brigitte Gicquel
  • Publication number: 20080014588
    Abstract: The present invention pertains to polynucleotides derived from M. tuberculosis genes imparting resistance to antibiotics and chemically related compounds. This invention also relates to the use of the polynucleotides as oligonucleotide primers or probes for detecting M. tuberculosis strains that are resistant to antibiotics and related compounds in a biological sample. Kits containing the primers and probes are also provided.
    Type: Application
    Filed: May 9, 2007
    Publication date: January 17, 2008
    Inventor: Brigitte Gicquel
  • Patent number: 7264815
    Abstract: This invention relates to a novel mycobacterial protein named DES, which appears to share significant amino acid sequence homology with soluble stearoyl-ACP desaturases. The results of allelic exchange experiments, indicate that the des gene may be essential to the survival of mycobacteria. These results coupled with the surface localization, the unique structure of DES, and the fact this antigen is expressed in vivo, and DES protein induces a humoral response in human patients, indicate that the DES protein provides a new target for the design of anti-mycobacterial drugs. This invention provides methods of screening molecules that can inhibit the DES enzyme activity of purified DES protein, in order to identify antibiotic molecules that are capable of inhibiting the growth or survival of mycobacteria.
    Type: Grant
    Filed: January 4, 2006
    Date of Patent: September 4, 2007
    Assignee: Institut Pasteur
    Inventors: Mary Jackson, Brigitte Gicquel
  • Patent number: 7247430
    Abstract: The present invention pertains to polynucleotides derived from M. tuberculosis genes imparting resistance to antibiotics and chemically related compounds. This invention also relates to the use of the polynucleotides as oligonucleotide primers or probes for detecting M. tuberculosis strains that are resistant to antibiotics and related compounds in a biological sample. Kits containing the primers and probes are also provided.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: July 24, 2007
    Assignee: Institut Pasteur
    Inventor: Brigitte Gicquel
  • Patent number: 7244613
    Abstract: The invention concerns recombinant vectors replicated in mycobacteria, a set of sequences coding for exported polypeptides detected by fusion with alkaline phosphatase, in particular one polypeptide, called DP428, of about 12 kD corresponding to an exported protein found in mycobacteria belonging to the Mycobacterium tuberculosis complex. The invention also concerns methods and kits for detecting in vitro the presence of a mycobacterium and in particular a mycobacterium belonging to the Mycobacterium tuberculosis complex in a biological sample using said polypeptides, their fragments or polynucleotides coding for the latter. The invention also concerns immunogenic or vaccine compositions for preventing and/or treating infections caused by mycobacteria and in particular a mycobacterium belonging to said complex, particularly tuberculosis.
    Type: Grant
    Filed: May 16, 2001
    Date of Patent: July 17, 2007
    Assignee: Institut Pasteur
    Inventors: Brigitte Gicquel, Denis Portnoï, Eng-Mong Lim, Vladimir Pelicic, Agnès Guigueno, Yves Goguet De La Salmoniere
  • Publication number: 20070015173
    Abstract: Purified polynucleotides and polypeptides, and cells of M. smegmatis, M. bovis, M. bovis BCG, or M. africanum are provided.
    Type: Application
    Filed: January 11, 2006
    Publication date: January 18, 2007
    Inventors: Brigitte Gicquel, Denis Portnoi, Eng-Mong Lim, Vladimir Pelicic, Agnes Guigueno, Yves Goguet De La Salmoniere
  • Patent number: 7160548
    Abstract: Mycobacterium strains in which the erp gene is modified, and vaccine compositions comprising such Mycobacterium strains are provided. The modification of the erp gene may decrease the virulence and the persistence of the Mycobacterium strains.
    Type: Grant
    Filed: September 30, 2002
    Date of Patent: January 9, 2007
    Assignee: Institit Pasteur
    Inventors: Brigitte Gicquel, François-Xavier Berthet
  • Publication number: 20060241291
    Abstract: Antibodies that bind to the M. Tuberculosis des gene are provided.
    Type: Application
    Filed: February 21, 2006
    Publication date: October 26, 2006
    Inventors: Mary Jackson, Brigitte Gicquel
  • Patent number: 7071320
    Abstract: The use of genetic methodology based on the fusion of the proteins with the alcaline phosphatase (Lim et al., 1995) has allowed the isolation of a new exported protein of M. tuberculosis. In the present article, first of all the isolation of a gene encoding this exported protein called DES is described as well as its characterization and its distribution among the different mycrobacterial species. It is notably shown that the protein has in its primary sequence amino acids only found at the level of active sites of enzymes of class II diiron-oxo proteins family. Among the proteins of this family, DES protein of M. tuberculosis does not present significative homologies with stearoyl ACP desaturases. Secondly, the antigenic feature of this protein has been studied. For this, DES protein of M. tuberculosis has been overexpressed in E. coli under recombinant and purified protein form from this bacterium. The reactivity of tuberculous patients sera infected by M. tuberculosis or M.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: July 4, 2006
    Assignee: Institut Pasteur
    Inventors: Mary Jackson, Brigitte Gicquel
  • Patent number: 7067136
    Abstract: This invention relates to a novel mycobacterial protein named DES, which appears to share significant amino acid sequence homology with soluble stearoyl-ACP desaturases. The results of allelic exchange experiments, indicate that the des gene may be essential to the survival of mycobacteria. These results coupled with the surface localization, the unique structure of DES, and the fact this antigen is expressed in vivo, and DES protein induces a humoral response in human patients, indicate that the DES protein provides a new target for the design of anti-mycobacterial drugs. This invention provides methods of screening molecules that can inhibit the DES enzyme activity of purified DES protein, in order to identify antibiotic molecules that are capable of inhibiting the growth or survival of mycobacteria.
    Type: Grant
    Filed: August 10, 2004
    Date of Patent: June 27, 2006
    Assignee: Institut Pasteur
    Inventors: Mary Jackson, Brigitte Gicquel
  • Publication number: 20060127959
    Abstract: Purified antibodies that bind to M. tuberculosis ERP protein are disclosed. In one a embodiment, a purified antibody, which binds specifically with a polypeptide comprising SEQ ID NO: 39 or SEQ ID NO: 41 is provided. In some embodiments the polypeptide has a theoretical molecular weight of about 28 kDa. In other embodiments the polypeptide has an observed molecular weight of about 36 kDa, as determined by denaturing polyacrylamide gel electrophoresis (SDS-PAGE). The purified antibody may be a monoclonal or a polyclonal antibody. Further embodiments provide antibodies that does not bind specifically with M. teprae P28 protein. The antibodies of the invention have many uses including the identification of M. tuberculosis.
    Type: Application
    Filed: January 15, 2003
    Publication date: June 15, 2006
    Applicant: Institut Pasteur
    Inventors: Brigitte Gicquel, Eng Lim, Denis Portnoi, Francois-Xavier Berthet, Juliano Timm
  • Publication number: 20060115497
    Abstract: The invention concerns Mycobacterium strains whereof the erp gene is modified and a vaccine composition containing same. The modification of the erp gene decreases the virulence and the persistence of the Mycobacterium strains.
    Type: Application
    Filed: January 26, 2006
    Publication date: June 1, 2006
    Inventors: Brigitte Gicquel, Francois-Xavier Berthet
  • Publication number: 20060099221
    Abstract: This invention relates to a novel mycobacterial protein named DES, which appears to share significant amino acid sequence homology with soluble stearoyl-ACP desaturases. The results of allelic exchange experiments, indicate that the des gene may be essential to the survival of mycobacteria. These results coupled with the surface localization, the unique structure of DES, and the fact this antigen is expressed in vivo, and DES protein induces a humoral response in human patients, indicate that the DES protein provides a new target for the design of anti-mycobacterial drugs. This invention provides methods of screening molecules that can inhibit the DES enzyme activity of purified DES protein, in order to identify antibiotic molecules that are capable of inhibiting the growth or survival of mycobacteria.
    Type: Application
    Filed: January 4, 2006
    Publication date: May 11, 2006
    Inventors: Mary Jackson, Brigitte Gicquel